AVC-203 / AvenCell Therap - LARVOL DELTA

AvenCell Therapeutics Announces IND Clearance and EMA Approval of Clinical Trial Application (CTA) for the QUADvance Study, a Phase I/II trial evaluating AVC-203, a Novel Allogeneic CD19/CD20 CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-cell malignancies (PRNewswire) - "The phase I/II study will be conducted at multiple sites in the US and Europe and will evaluate the safety, tolerability, efficacy, and pharmacokinetics of AVC-203 in adults with relapsed or refractory B-cell malignancies. The phase Ia dose escalation study is expected to be followed by a phase Ib dose expansion study and a Phase II pivotal trial."

IND • New P1/2 trial • B Cell Non-Hodgkin Lymphoma

ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers (Businesswire) - "ViroCell Biologics...announces a manufacturing collaboration with and the successful delivery of a novel retroviral vector to AvenCell Therapeutics, Inc. ('AvenCell'), a leading clinical-stage cell therapy company focused on advancing allogeneic switchable CAR-T cell therapies. This first retroviral vector will be used to manufacture AVC-203, an investigational CD19/CD20 dual-targeted cell therapy for the treatment of B cell malignancies and autoimmune diseases....AvenCell selected ViroCell as its partner to manufacture the retroviral vector for this program based on the CDMO’s expertise and track record in delivering high yield vectors at speed....AvenCell’s AVC-203 is expected to enter a first-in-human phase I study in patients with relapsed/refractory B cell lymphoma in H2/2025."

Commercial • New P1 trial • B Cell Lymphoma • Immunology

AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program (PRNewswire) - "AvenCell Japan...announced it has been awarded a grant of up to $40 million from the Japan Agency for Medical Research and Development (AMED). This non-dilutive funding will support the worldwide development of AvenCell's AVC203 candidate - an IND-stage, dual-antigen (CD19 & CD20) allogeneic CAR-T therapy for applications in B-cell Lymphomas."

Financing • B Cell Lymphoma